Published June 4, 2026 | Version v1
Other Open

What is the efficacy of crizanlizumab in reducing the frequency and intensity of vaso-occlusive crises in patients with sickle cell disease?

Authors/Creators

  • 1. Tripdatabase

Description

Crizanlizumab has been shown to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease based on both clinical trials and real-world data, though some trials have shown mixed results.

Files

87a54ba1-a23f-4a8a-b28b-af8a793dc1cc.pdf

Files (18.5 kB)

Name Size Download all
md5:6a2ba59b161efb11ba4b1e5ac6157953
18.5 kB Preview Download

Additional details

Related works

Is identical to
https://www.tripdatabase.com/ask/efficacy-of-crizanlizumab-in-reducing-vaso-occlusive-crises-in-sickle-cell-disease-87a54ba1-a23f-4a8a-b28b-af8a793dc1cc (URL)